Specific Dietary Pattern for Crohn's Disease Patients Following Surgery

Effectiveness and Pathogenesis of Specific Dietary Pattern in Maintaining Remission Among Crohn's Disease(CD) Patients Following Surgery

Over the past 10 years, there are a large number of dietary treatments related to the CD, such as specific carbohydrate diet, low Fermentable Oligo-, Di-, Mono-saccharides And Polyols (FODMAP) diet, and allergen-free foods. But there is no consistent conclusion or convincing evidence about the effectiveness. Through the long-term clinical experience observation, we find most of the CD patients can get stable remission by removing refined food and intolerance food.This project aims at developing a new dietary therapy suitable for Chinese patients.

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Detailed Description

The dietary therapy is based on the nutrient composition of exclusive enteral nutrition and is more in line with Chinese patients' dietary habits and economic conditions.

Study Type

Interventional

Enrollment (Estimated)

35

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

    • Zhejiang
      • Hangzhou, Zhejiang, China, 310009
        • Recruiting
        • 2nd Affiliated Hospital, School of Medicine, Zhejiang University
        • Contact:
          • huang xiaoxu

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

14 years and older (Child, Adult, Older Adult)

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  1. Diagnose CD according to endoscopy, histology and imaging;
  2. Bowel resection for CD
  3. Oral nutritional preparations or food can be given after surgery

Exclusion Criteria:

  1. Plan operation within 5 weeks after surgery;
  2. Presence of an ileostomy or colostomy
  3. Complete bowel obstruction or fibrous stricture
  4. Pregnancy or breastfeeding;
  5. Plan to use biological agents within 5 weeks after surgery;
  6. Plan to use corticosteroids or prednisone greater than 20 mg per day or equivalent doses of drugs to maintain remission within 5 weeks after surgery;
  7. Plan to use probiotics or prebiotics for more than 1 week after surgery;
  8. Antibiotics are used for more than 2 weeks after surgery;
  9. Hypersensitivity to known components of enteral nutrition;
  10. BMI less than 14 or greater than 28 kg/m2;
  11. Celiac disease;
  12. Complicated with other autoimmune diseases such as diabetes or rheumatic disease, autoimmune liver disease, psoriasis;
  13. Mental illness;
  14. Malignant tumors
  15. Those who are not suitable for body composition analysis (such as pacemakers and metal objects in the body)
  16. Participating in other clinical trials
  17. The researcher believes that others are not suitable to participate in this study.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Health Services Research
  • Allocation: Randomized
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: Exclusive Enteral Nutrition(EEN)
Subjects required exclusive enteral nutrition for one month
All energy and nutrients are obtained from exclusive enteral nutrition.
Experimental: Specific Diet+ Partial Enteral Nutrition
Subjects received partial enteral nutrition with remaining energy and nutrients obtained through diet for one month
Reprocessed and intolerant foods were removed from the dietary pattern, and the food were cooked at home for experimental subjects.
Other Names:
  • dietary guidance

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Quality of Life(IBDQ)
Time Frame: The two groups of patients were scored at first week and sixth week after surgery.
IBDQ: Inflammatory Bowel Disease Questionnaire.The IBDQ evaluates the quality of life of patients from four aspects: intestinal symptoms, systemic symptoms, emotional function and social function. There are 32 questions in the questionnaire, with a total score of 32 to 224 points. The higher the score, the higher the quality of life of the patient.
The two groups of patients were scored at first week and sixth week after surgery.

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
nutritional status of the patient
Time Frame: The two groups were evaluated at first week and sixth week after surgery.
Body composition analysis, calf circumference in centimeter , albumin in g/L, hemoglobin in g/L, were measured to evaluate the nutritional status
The two groups were evaluated at first week and sixth week after surgery.
Disease-related evaluation indicators
Time Frame: The two groups were evaluated at first week and sixth week after surgery.
We assessed the effect of the intervention on disease by measuring the following indicators: Harvey-Bradshaw Index(HBI), Crohn's Disease Activity Index (CDAI), C Reactive Protein (CRP)in mg/L, Erythrocyte Sedimentation Rate (ESR) in mm/h, platelets in 10^9/L, triglycerides in m mol/L, cholesterol in m mol/L , uric acid in u mol/L.
The two groups were evaluated at first week and sixth week after surgery.

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
dietary compliance
Time Frame: The two groups were evaluated at sixth week after surgery.
Modified medication adherence was measured, with < 6 points defined as low adherence, 6 to 8 points defined as moderate adherence, and > 8 points defined as high adherence
The two groups were evaluated at sixth week after surgery.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: yu qiao, 2nd Affiliated Hospital, School of Medicine, Zhejiang University, China
  • Study Director: guo huilan, 2nd Affiliated Hospital, School of Medicine, Zhejiang University, China

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

September 17, 2022

Primary Completion (Estimated)

June 30, 2026

Study Completion (Estimated)

June 30, 2026

Study Registration Dates

First Submitted

August 11, 2022

First Submitted That Met QC Criteria

August 14, 2022

First Posted (Actual)

August 16, 2022

Study Record Updates

Last Update Posted (Actual)

February 2, 2026

Last Update Submitted That Met QC Criteria

January 29, 2026

Last Verified

January 1, 2026

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Crohn Disease

Clinical Trials on EEN

Subscribe